Jefferies Group LLC Cytom X Therapeutics, Inc. Transaction History

Jefferies Group LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.67 - $4.68 $88,772 - $155,600	-33,248 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.87 - $7.39 $128,669 - $245,702	33,248 New	33,248 $69,000
Q4 2019 Feb 13, 2020	SELL	$5.17 - $8.91 $151,713 - $261,463	-29,345 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$7.38 - $12.25 $216,566 - $359,476	29,345 New	29,345 $217,000
Q3 2018 Nov 14, 2018	SELL	$18.04 - $26.41 $46,020 - $67,371	-2,551 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$21.38 - $29.68 $912,134 - $1.27 Million	-42,663 Reduced 94.36%	2,551 $58,000
Q1 2018 May 15, 2018	BUY	$21.76 - $34.22 $983,856 - $1.55 Million	45,214 New	45,214 $1.29 Million

50.2M

22.3K

22.9K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $79.1M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.